Insights

In recognition of September being World Alzheimer’s Month (a campaign of Alzheimer’s Disease International), ACRP sought out commentary on a type of therapy for the disease that’s not as well known to the public as the recently approved pharmaceuticals lacanemab (Leqembi® from Eisai Inc. and Biogen) or donanemab (Kisunla™ from Eli Lilly), or the much older mematine (now marketed under many brand names worldwide). 

As students and faculty began settling into the routines of a new academic year at colleges and universities across the U.S., ACRP reached out to experts from graduate programs in clinical research for a snapshot of how education in this field, especially at the master’s degree level, is holding up amidst rapidly evolving changes in the research enterprise itself.

Artificial intelligence could be leveraged to reduce the administrative burden associated with laborious, site-specific documents to provide clinical trial teams more time to conduct high-priority tasks such as identifying, screening, and enrolling patients.

It’s no secret that the clinical research enterprise faces many struggles related to attracting and retaining qualified physicians to serve as principal investigators (PIs) for clinical trials. All too often, the first trial a PI completes is also their last one. However, when someone with a passion for research takes on the PI mantle as a true calling, it becomes part of their professional and personal identities. 

One of the most common and important types of quality management measures in clinical research is the Corrective and Preventive Action (CAPA) plan. Learning the CAPA process will provide insight into how corrective and preventive actions are handled, along with creating an effective game plan for your use of CAPAs.